Helix announced that it has received US$50 million in Series C funding to continue to accelerate its entry into clinical population genomics and COVID-19 virus surveillance


San Mateo, California, June 3, 2021 /PRNewswire/ – spiral, A leading demographic genomics and COVID-19 testing company, has completed the investment by existing investors Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic and Temasek.This 50 million USD This round of financing will be used to accelerate the organization’s population genome platform across health systems, life science companies, and payers, and to provide impetus for its growing COVID-19 testing and virus surveillance efforts.

Helix announced 50 million USD Accelerated access to C-series funding for clinical population genomics and COVID virus surveillance

Helix’s end-to-end genomics platform enables organizations to advance genomic research and accelerate the integration of genomic data into clinical care through its unique “sequence once, often query™” model. Using this model, personal DNA can be collected, sequenced, and safely stored at one time, while allowing continuous access to genomic data and insights as needed, without the need to collect additional saliva samples.

“In the healthcare field, the goal is to achieve more personalized, preventive, and population-based healthcare. One of the core components is to identify people at risk of genetic diseases earlier and more widely,” Amr Kronfol, Managing Director of Warburg Pincus Investment Say. “Helix has a proven and tested platform for generating high-quality genomic data, protecting it, and making it portable so that it can provide health systems, life science companies, and payers working for a healthier world Lifelong insights.”

Helix used its proprietary Exome+® assay to sequence approximately 20,000 protein-coding genes and 300,000 informative non-coding regions, creating a powerful genome map. Health systems, life science companies, and payers use this data to drive innovative population health programs, help improve health outcomes, increase patient engagement, and accelerate innovative research. In addition, Helix is ​​using its expertise in large-scale next-generation sequencing to promote its rapidly growing virus monitoring products to help organizations detect, characterize and better understand the impact of emerging COVID-19 strains.

“Understanding the genomic makeup of an individual is leading the development of more personalized and customized health products,” said James Lu, MD, PhD, co-founder and CEO of Helix. “The new FDA pathway we created for the Helix ® laboratory platform means that Helix and our partners will be able to use a subset of the sequencing data generated by the platform to develop and obtain market authorization for future tests, including cancer, cardiovascular disease, and carriers Screening.”

Helix operates one of the world’s largest CLIA-certified and CAP-accredited next-generation sequencing laboratories to support its Exome+® and COVID-19 virus sequencing work.in January 2021, The Helix laboratory platform has obtained the FDA’s first and only authorization for the whole exome sequencing platform. Since its establishment in 2015, Helix has helped hundreds of thousands of people improve their lives through their DNA, including through large-scale population health programs, including Renown Health’s Healthy Nevada Project and Mayo Clinic’s Tapestry Program.

About the spiral

Helix is ​​a leading population genomics company, operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life science companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Supported by one of the world’s largest CLIA/CAP next-generation sequencing laboratories and the first and only FDA-authorized whole-exome sequencing platform, Helix supports all aspects of population genomics, including recruitment and participation, clinical Feasible disease screening, result return, and basic and translational research. In response to the COVID-19 public health crisis, Helix has launched a sensitive and scalable end-to-end COVID-19 testing system to meet the needs of the national health system, employers, governments, and other organizations.to know more information www.helix.com.

Media contact
Amy Fisher, Padilla
612.805.5707
[email protected]

Caesarean section View original content and download multimedia:http://www.prnewswire.com/news-releases/helix-announces-50-million-series-c-funding-to-continue-acceleration-into-clinical-population-genomics-and-covid-19-viral- Monitoring-301305460.html

Source spiral



Source link

Recommended For You

About the Author: Brand Story